Parsatuzumab

National Cancer Institute

Source

National Cancer Institute. Parsatuzumab. NCI Thesaurus. Code C90567.

A humanized IgG1 monoclonal antibody directed against the epidermal growth factor-like domain multiple 7 (EGFL7) with potential antineoplastic activity. Parsatuzumab binds to EGFL7, thereby preventing the activities of EGFL7 on endothelial cells and inhibiting the survival and migration of endothelial cells during angiogenesis. EGFL7, a vascular-restricted extracellular matrix protein which is upregulated during angiogenesis and which regulates vascular development, may be overexpressed on the cell surfaces of various solid tumor cell types.